Study to Investigate the Treatment Benefits of Probiotic Streptococcus Salivarius K12 for Mild-to-moderate COVID-19
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a randomised, open-label and controlled clinical trial aimed to investigate the
adjuvant treatment benefits of probiotic Streptococcus salivarius K12 in hospitalised
mild-to-moderate patients with COVID-19 disease.